Insights into Apoptosis Mechanisms Induced by DNA-Damaging Agents in Burkitt's Lymphoma Cells

REFERENCES

• Lane D. P. Cancer. p53, guardian of the genome. Nature 1992; 358(6381)15–16
   PubMed Web of Science ®Google Scholar
• Vogelstein B., Kinzler K. W. p53 function and dysfunction. Cell 1992; 70(4)523–526
   PubMed Web of Science ®Google Scholar
• Chipuk J. E., Maurer U., Green D. R., Schuler M. Pharmacologic activation of p53 elicits Bax-dependent apoptosis in the absence of transcription. Cancer Cell 2003; 4(5)371–381
   PubMed Web of Science ®Google Scholar
• Chipuk J. E., Green D. R. Cytoplasmic p53: bax and forward. Cell Cycle 2004; 3(4)429–431
   PubMed Web of Science ®Google Scholar
• Thompson C. B. Apoptosis in the pathogenesis and treatment of disease. Science 1995; 267(5293)1456–1462
   PubMedGoogle Scholar
• Duckett C. S., Nava V. E., Gedrich R. W., Clem R. J., Van Dongen J. L., Gilfillan M. C., Shiels H., Hardwick J. M., Thompson C. B. A conserved family of cellular genes related to the baculovirus iap gene and encoding apoptosis inhibitors. EMBO J 1996; 15(11)2685–2694
   PubMed Web of Science ®Google Scholar
• Ambrosini G., Adida C., Altieri D. C. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997; 3(8)917–921
   PubMed Web of Science ®Google Scholar
• Altieri D. C. The molecular basis and potential role of survivin in cancer diagnosis and therapy. Trends Mol Med 2001; 7(12)542–547
   PubMed Web of Science ®Google Scholar
• Stauber R. H., Mann W., Knauer S. K. Nuclear and cytoplasmic survivin: molecular mechanism, prognostic and therapeutic potential. Cancer Res 2007; 67(13)5999–6002
   PubMed Web of Science ®Google Scholar
• Li F., Ambrosini G., Chu E. Y., Plescia J., Tognin S., Marchisio P. C., Altieri D. C. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 1998; 396(6711)580–584
   PubMed Web of Science ®Google Scholar
• Hoffman W. H., Biade S., Zilfou J. T., Chen J., Murphy M. Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J Biol Chem 2002; 277(5)3247–3257
   PubMed Web of Science ®Google Scholar
• Zhou M., Gu L., Li F., Zhu Y., Woods W. G., Findley H. W. DNA damage induces a novel p53-survivin signaling pathway regulating cell cycle and apoptosis in acute lymphoblastic leukemia cells. J Pharmacol Exp Ther 2002; 303(1)124–131
   PubMed Web of Science ®Google Scholar
• Farrell P. J., Allan G. J., Shanahan F., Vousden K. H., Crook T. p53 is frequently mutated in Burkitt's lymphoma cell lines. EMBO J 1991; 10(10)2879–2887
   PubMed Web of Science ®Google Scholar
• Debuire B., Romano J., Ehrhart J. C., Fiscella M., May E., Appella E., May P. p53 mutations in Raji cells: characterization and localization relative to other Burkitt's lymphomas. Oncogene 1992; 7(11)2161–2167
   PubMed Web of Science ®Google Scholar
• Gaidano G., Ballerini P., Gong J. Z., Inghirami G., Neri A., Newcomb E. W., Magrath I. T., Knowles D. M., Dalla-Favera R. p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia. Proc Natl Acad Sci U.S.A. 1991; 88(12)5413–5417
   PubMed Web of Science ®Google Scholar
• Seabright M. A. A rapid banding technique for human chromosomes. Lancet 1971; 2(7731)971–972
   PubMed Web of Science ®Google Scholar
• Drexler H. G., Dirks W. G., Matsuo Y., MacLeod R. A. False leukemia-lymphoma cell lines: an update on over 500 cell lines. Leukemia 2003; 17(2)416–426
   PubMed Web of Science ®Google Scholar
• Karpova M. B., Schoumans J., Ernberg I., Henter J. I., Nordenskjöld M., Fadeel B. Raji revisited: cytogenetics of the original Burkitt's lymphoma cell line. Leukemia 2005; 19(1)159–161
   PubMed Web of Science ®Google Scholar
• Karpova M. B., Schoumans J., Blennow E., Ernberg I., Henter J. I., Smirnov A. F., Nordenskjöld M., Fadeel B. Combined spectral karyotyping, comparative genomic hybridization, and in vitro apoptyping of a panel of Burkitt's lymphoma-derived B cell lines reveals an unexpected complexity of chromosomal aberrations and a recurrence of specific abnormalities in chemoresistant cell lines. Int J Oncol 2006; 28(3)605–617
   PubMed Web of Science ®Google Scholar
• Benchimol S. p53-dependent pathways of apoptosis. Cell Death Differ 2001; 8(11)1049–1051
   PubMed Web of Science ®Google Scholar
• Klumb C. E., Furtado D. R., de Resende L. M., Carriço M. K., Coelho A. M., de Meis E., Maia R. C., Rumjanek F. D. DNA sequence profile of TP53 gene mutations in childhood B-cell non-Hodgkin's lymphomas: prognostic implications. Eur J Haematol 2003; 71(2)81–90
   PubMed Web of Science ®Google Scholar
• Brown J. M., Wouters B. G. Apoptosis, p53, and tumor cell sensitivity to anticancer agents. Cancer Res 1999; 59(7)1391–1399
   PubMed Web of Science ®Google Scholar
• Soussi T., Béroud C. Assessing TP53 status in human tumours to evaluate clinical outcome. Nat Rev Cancer 2001; 1(3)233–240
   PubMed Web of Science ®Google Scholar
• O'Connor P. M., Jackman J., Jondle D., Bhatia K., Magrath I., Kohn K. W. Role of the p53 tumor suppressor gene in cell cycle arrest and radiosensitivity of Burkitt's lymphoma cell lines. Cancer Res 1993; 53(20)4776–4780
   PubMed Web of Science ®Google Scholar
• Fan S., el-Deiry W. S., Bae I., Freeman J., Jondle D., Bhatia K., Fornace A. J., Jr., Magrath I., Kohn K. W., O'Connor P. M. p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents. Cancer Res 1994; 54(22)5824–5830
   PubMed Web of Science ®Google Scholar
• Allday M. J., Inman G. J., Crawford D. H., Farrell P. J. DNA damage in human B cells can induce apoptosis, proceeding from G1/S when p53 is transactivation competent and G2/M when it is transactivation defective. EMBO J 1995; 14(20)4994–5005
   PubMed Web of Science ®Google Scholar
• Ryan K. M., Vousden K. H. Characterization of structural p53 mutants which show selective defects in apoptosis but not cell cycle arrest. Mol Cell Biol 1998; 18(7)3692–3698
   PubMed Web of Science ®Google Scholar
• Rowan S., Ludwig R. L., Haupt Y., Bates S., Lu X., Oren M., Vousden K. H. Specific loss of apoptotic but not cell-cycle arrest function in a human tumor derived p53 mutant. EMBO J 1996; 15(4)827–838
   PubMed Web of Science ®Google Scholar
• Kakudo Y., Shibata H., Otsuka K., Kato S., Ishioka C. Lack of correlation between p53-dependent transcriptional activity and the ability to induce apoptosis among 179 mutant p53s. Cancer Res 2005; 65(6)2108–2114
   PubMed Web of Science ®Google Scholar
• Doucet J. P., Hussain A., Al-Rasheed M., Gaidano G., Gutiérrez M. I., Magrath I., Bhatia K. Differences in the expression of apoptotic proteins in Burkitt's lymphoma cell lines: potential models for screening apoptosis-inducing agents. Leuk Lymphoma 2004; 45(2)357–362
   PubMed Web of Science ®Google Scholar
• Wade M., Allday M. J. Epstein-Barr virus suppresses a G(2)/M checkpoint activated by genotoxins. Mol Cell Biol 2000; 20(4)1344–1360
   PubMed Web of Science ®Google Scholar
• Kelly G. L., Milner A. E., Tierney R. J., Croom-Carter D. S., Altmann M., Hammerschmidt W., Bell A. I., Rickinson A. B. Epstein-Barr virus nuclear antigen 2 (EBNA2) gene deletion is consistently linked with EBNA3A, -3B, and -3C expression in Burkitt's lymphoma cells and with increased resistance to apoptosis. J Virol 2005; 79(16)10709–10717
   PubMed Web of Science ®Google Scholar
• Leao M., Anderton E., Wade M., Meekings K., Allday M. J. Epstein-Barr virus-induced resistance to drugs that activate the mitotic spindle assembly checkpoint in Burkitt's lymphoma cells. J Virol 2007; 81(1)248–260
   PubMed Web of Science ®Google Scholar
• Lindström M. S., Klangby U., Wiman K. G. p14ARF homozygous deletion or MDM2 overexpression in Burkitt lymphoma lines carrying wild type p53. Oncogene 2001; 20: 2171–2177
   PubMed Web of Science ®Google Scholar